MTNB matinasbiopharma.com Earnings growth forecast for next year

Matinas BioPharma (MTNB) management is demonstrating transparency in the LNC system and MAT2203 trials while effectively protecting intellectual property. The valuation of expected EPS growth for the coming year confirms market optimism, where the 0.00 level serves as the current metric. Matinas BioPharma (MTNB) is diversifying its anti-inflammatory developments by implementing oral administration. These R&D solutions enable the replacement of injections with convenient tablets, expanding access to mass markets.

Matinas BioPharma Holdings Inc. (MTNB): Expected net earnings per share growth next year from 07/04/2022 to 11/14/2026

MTNB (Matinas BioPharma Holdings Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:

Stock Price Matinas BioPharma Holdings Inc.|MTNB - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Matinas BioPharma Holdings, Inc.|MTNB - Total Company Value

- book capitalization indicators:

Net Assets per Single Share Matinas BioPharma|MTNB - Total Stockholders' Equity|Market Value to Book Value Ratio matinasbiopharma.com|MTNB - Aggregate Company Assets

- debt and solvency information:

Total Debt to Capital Matinas BioPharma|MTNB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Matinas BioPharma Holdings|MTNB - Company Total Debt Obligations|Debt to Book Capitalization Ratio Matinas BioPharma Holdings Inc.|MTNB - Company Long-Term Liabilities|Company Short-Term Debt Matinas BioPharma|Quick Ratio matinasbiopharma.com

- net income and valuation ratios data:

MTNB - Net Profit|Future Profit Matinas BioPharma|MTNB - Market Price to Net Income Ratio|Forward P/E Multiple Matinas BioPharma Holdings|MTNB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Matinas BioPharma|MTNB - Operating profit before amortization|Net earnings per share (EPS TTM) Matinas BioPharma|MTNB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months matinasbiopharma.com|MTNB - Expected net earnings per share growth this year|Expected earnings per share growth for next year Matinas BioPharma

- total revenue and sales volume data:

MTNB - Company Sales Revenue|Projected Sales Volume Matinas BioPharma|MTNB - Price-to-Revenue Ratio|Forward P/S Multiple Matinas BioPharma

Initial company analysis:MTNB, Matinas BioPharma Holdings, Inc.

Finished products of Matinas BioPharma Holdings, Inc.

This indicator measures the consensus earnings per share (EPS) forecast, reflecting the balance between institutional expectations and the business's actual ability to absorb costs. The current value of 0.00 allows for an assessment of asset overvaluation risk, while the projected EPS growth rate for next year depends directly on the expansion of the licensee pool and the success of Matinas BioPharma (MTNB) joint developments in the complex molecule delivery segment.

Analysis of competing companies